BIOMAT Database Logo BIOMAT Database Logo

Anti-inflammatory and antinociceptive effects of the selective cannabinoid CB2 receptor agonist ABK5. 2021

Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, 06269, USA.

Cannabinoid receptors are a potential target for anti-inflammatory and pain therapeutics. There are two subtypes, CB1 and CB2, and Δ9-tetrahydrocannabinol activates both of them, providing an analgesic effect but also psychoactive side effects. The psychoactive side effects are considered to be caused by activation of CB1, but not CB2. ABK5 is a CB2 subtype selective agonist that has a very different structure from known cannabinoid receptor agonists. Here, we report anti-inflammatory effects of ABK5 using the T-cell line Jurkat cells, and antinociceptive effect in an inflammatory pain model in rats. Production of the cytokines IL-2 and TNF-α was measured in stimulated Jurkat cells and MOLT-4 cells, and CXCL12-mediated chemotaxis of Jurkat cells was evaluated by a transwell migration assay. Anti-inflammatory and antinociceptive effects of ABK5 were also evaluated in a hindpaw CFA model in rats. ABK5 significantly decreased production of IL-2 and TNF-α measured as both mRNA and protein levels, and reduced chemotaxis towards CXCL12. It also attenuated edema and increased mechanical threshold in the hindpaw of CFA-treated rats. These results suggest that ABK5 is a good lead compound for the development of potential anti-inflammatory and analgesic agents.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D002633 Chemotaxis The movement of cells or organisms toward or away from a substance in response to its concentration gradient. Haptotaxis
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000700 Analgesics Compounds capable of relieving pain without the loss of CONSCIOUSNESS. Analgesic,Anodynes,Antinociceptive Agents,Analgesic Agents,Analgesic Drugs,Agents, Analgesic,Agents, Antinociceptive,Drugs, Analgesic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D001565 Benzoates Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure. Benzoate,Benzoic Acids,Acids, Benzoic

Related Publications

Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
Anti-Inflammatory Activity of a CB2 Selective Cannabinoid Receptor Agonist: Signaling and Cytokines Release in Blood Mononuclear Cells.
December 2021, Molecules (Basel, Switzerland),
Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models.
June 2013, Pain,
Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.
January 2011, Neuropharmacology,
Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells.
July 2018, International journal of molecular sciences,
Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
Cannabichromene is a cannabinoid CB2 receptor agonist.
December 2019, British journal of pharmacology,
Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966.
January 2022, Frontiers in pharmacology,
Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
SR144528 as inverse agonist of CB2 cannabinoid receptor.
September 2002, Journal of veterinary science,
Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
September 2009, Neuropharmacology,
Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects.
August 2018, Toxicology and applied pharmacology,
Yaliang Tang, and Barbara Wolk, and Stevie C Britch, and Rebecca M Craft, and Debra A Kendall
A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
December 2005, European journal of pharmacology,
Copied contents to your clipboard!